Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling

Breast Cancer Research and Treatment

Volumn 142, Issue 2, 2013, Pages 271-282

  Gorczynski, Reginald M ^a,b   Chen, Zhiqi ^a   Khatri, Ismat ^a   Podnos, Anna ^a   Yu, Kai ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; CD200R1KO; Immunotherapy; Metastasis

Indexed keywords

CD200 ANTIGEN; CD200 RECEPTOR; CPG OLIGODEOXYNUCLEOTIDE; OKT 4; OKT 8;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; BREAST CANCER; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; KNOCKOUT MOUSE; LIVER METASTASIS; LONG TERM SURVIVAL; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD4; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOCYTES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; OLIGODEOXYRIBONUCLEOTIDES; SIGNAL TRANSDUCTION;

EID: 84890429833     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2735-3     Document Type: Article

References (41)

1. Petermann KB, Rozenberg GI, Zedek D et al (2007) CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 117:3922-3929
2. Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A (2008) Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 57:987-996
3. Moreaux J, Veyrune JL, Reme T, DeVos J, Klein B (2008) CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun 366:117-122
4. McWhirter JR, KretzRommel A, Saven A et al (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Nat Acad Sci USA 103:1041-1046
5. Tonks A (2007) CD200 as a prognostic factor in acute myeloid leukemia. Leukemia 21:566-568
6. Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL (2007) Co-expression of the tolerogenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 364:778-782
7. Gorczynski RM, Chen Z, Diao J et al (2010) Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat 123:405-415
8. Pandit TS, Kennette W, MacKenzie L et al (2009) Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment. Int J Oncol 35:297-308
9. Pfeffer U, Romeo F, Noonan DM, Albini A (2009) Prediction of breast cancer metastasis by genomic profiling: where do we stand? Clin Exp Metastasis 26:547-558
10. Hunter KW, Alsarraj J (2009) Gene expression profiles and breast cancer metastasis: a genetic perspective. Clin Exp Metastasis 26:497-503
11. Pollard JW (2008) Macrophages define the invasive microenvironment in breast cancer. J Leukocyte Biol 84:623-630
12. Olkhanud PB, Baatar D, Bodogai M et al (2009) Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 69:5996-6004
13. Lu X, Kang YB (2009) Chemokine (C-C motif) ligand 2 engages CCR2(+) stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem 284:29087-29096
14. Chen T, Jackson CR, Link A et al (2006) Int7G24A variant of transforming growth factor-beta receptor type 1 is assaociated with invasive breast cancer. Clin Cancer Res 12:392-397
15. Liang ZX, Yoon YH, Votaw J, Goodman MM, Williams L, Shim H (2005) Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 65:967-971
16. Takahashi M, Miyazaki H, Furihata M et al (2009) Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-metastatic mouse breast cancer model. Clin Exp Metastasis 26:817-828
17. Ma XR, Norsworthy K, Kundu N et al (2009) CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 8:490-498
18. Huang B, Pan PY, Li QS et al (2006) Gr-1(+)CD115(+) immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123-1131
19. Yang L, Debusk LM, Fukuda K et al (2004) Expansion of myeloid immune suppressor GR1+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409-421
20. Qin FXF (2009) Dynamic behavior and function of foxp3(+) regulatory T cells in tumor bearing host. Cell Mol Immunol 6:3-13
21. Yang L, Huang JH, Ren XB et al (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13:23-35
22. Gorczynski RM, Clark DA, Erin N, Khatri I (2011) Role of CD200 in regulation of metastasis of EMT6 tumor cells in mice. Breast Cancer Res Treat 130:49-60
23. Podnos A, Clark DA, Erin N, Yu K, Gorczynski RM (2012) Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6. Breast Cancer Res Treat 136:117-127
24. Yu K, Chen Z, Gorczynski R (2013) Effect of CD200 and CD200R1 expression within tissue grafts on increased graft survival in allogeneic recipients. Immunol Lett 149:1-8
25. Landrigan A, Wong MT, Utz PJ (2011) CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanism. J Immunol 187:3033-3043
26. -/- mice is dependent on the presence of STAT6-reactive T cells. J Immunol 170:2014-2021
27. Chaudhuri S, Cariappa A, Tang M (2000) Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci USA 97:11451-11454
28. Marincola FM, Jaffee EM, Hicklin DJ (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181-273
29. Camploi M, Changg CC, OLdford SA (2004) HLA antigen chnages in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications. Breast Dis 2004:105-125
30. Menard S, Tomasic G, Casalini P (1997) Lymphoid infiltration as a prognostic variable for early onset breast carcinomas. Clin Cancer Res 3:817-819
31. Disis ML, Calenoff E, McLaughlin G (1994) Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16-20
32. Jerome KR, Domenech N, Finn OJ (1993) Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 151:1654-1662
33. Baxevanis CN, Sotiriadou NN, Gritzapis AD et al (2006) Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother 55:85-95
34. Anderson KS (2009) Tumor vaccines for breast cancer. Cancer Invest 27:361-368
35. Zhou G, Drake CG, Levitsky HI (2006) Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107:628-636
36. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G (2013) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73:3591-3603
37. Novakovic S, Stegel V, Kopitar A, Han A, Novakovic BJ (2007) Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs. Vaccine 25:8241-8256
38. Yuan SF, Shi CH, Lv YG, Wang T, Wang H, Han W (2009) A novel bacillus calmette-guerin-based breast cancer vaccine that coexpresses multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth. Cancer Biother Radiopharm 24:607-613
39. Assudani DP, Horton RBV, Mathieu MG, McArdle SEB, Rees RC (2007) The role of CD4(+) T cell help in cancer immunity and the formulation of novel cancer vaccines. Cancer Immunol Immunother 56:70-80
40. Beyer M, Karbach J, Mallmann MR et al (2009) Cancer vaccine enhanced, non-tumor-reactive CD8(+) T cells exhibit a distinct molecular program associated with ''division arrest anergy''. Cancer Res 69:4346-4354
41. Nanni P, Nicoletti G, Palladini A et al (2007) Antimetastatic activity of a preventive cancer vaccine. Cancer Res 67:11037-11044